Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Receives $163.32 Consensus PT from … – WKRB News

Tweet

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has received a consensus rating of "Buy" from the thirty-two research firms that are currently covering the firm, AnalystRatings.Net reports. Two analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, eighteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $ 163.32.

Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 101.65 on Wednesday. The stock has a market capitalization of $ 34.88 billion and a P/E ratio of 58.39. Valeant Pharmaceuticals Intl has a 52 week low of $ 69.33 and a 52 week high of $ 263.81. The stock has a 50 day moving average of $ 95.14 and a 200 day moving average of $ 177.71.

Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings results on Monday, October 19th. The specialty pharmaceutical company reported $ 2.74 EPS for the quarter, topping the consensus estimate of $ 2.68 by $ 0.06. The company had revenue of $ 2.79 billion for the quarter, compared to analyst estimates of $ 2.06 billion. During the same quarter in the prior year, the business posted $ 0.58 earnings per share. The business's revenue for the quarter was up 35.5% compared to the same quarter last year. On average, equities research analysts predict that Valeant Pharmaceuticals Intl will post $ 2.89 earnings per share for the current fiscal year.

In other news, Director Ronald Harold Farmer acquired 1,500 shares of the stock in a transaction on Wednesday, October 21st. The shares were purchased at an average price of $ 181.60 per share, for a total transaction of $ 272,400.00. Following the transaction, the director now directly owns 15,532 shares of the company's stock, valued at $ 2,820,611.20. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

An institutional investor recently raised its position in Valeant Pharmaceuticals Intl stock. Meag Munich Ergo Kapitalanlagegesellschaft raised its position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) by 6.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,800 shares of the specialty pharmaceutical company's stock after buying an additional 4,600 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft's holdings in Valeant Pharmaceuticals Intl were worth $ 12,732,000 at the end of the most recent reporting period.

Several equities analysts recently weighed in on VRX shares. Stifel Nicolaus reaffirmed a "buy" rating and set a $ 285.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Sunday, November 1st. Mizuho raised shares of Valeant Pharmaceuticals Intl from a "neutral" rating to a "buy" rating and set a $ 155.00 price objective on the stock in a research report on Tuesday, October 27th. Bank of America reaffirmed a "buy" rating and set a $ 173.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Sunday, November 1st. CIBC started coverage on shares of Valeant Pharmaceuticals Intl in a research report on Monday, November 30th. They set a "sector perform" rating and a $ 90.00 price objective on the stock. Finally, Canaccord Genuity reaffirmed a "buy" rating and set a $ 235.00 price objective (down previously from $ 300.00) on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, October 8th.

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company's developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company's Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/990457/valeant-pharmaceuticals-intl-inc-nysevrx-receives-163-32-consensus-pt-from-brokerages/

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com’s FREE daily email newsletter.